A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...

CHICAGO -- Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced the risk of disease ...

Oncology experts from all over the world will discuss the latest developments in care. The American Society of Clinical ...

Silicosis is caused by inhaling crystalline silica dust, which is generated by cutting, polishing or grinding stones, ...

The International Association of Top Professionals (IAOTP) will honor Dr. Kara Roncin at their Annual Awards Gala in ...

Collecting BMI data could further research into why women with lung cancer have better survival outcomes than men.An ...

For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the ...

AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance ...

In Applying EMPOWER-Lung 3 to Clinical Practice: Population Relevance, Histology, and PD-L1 Considerations, our panel delve into the following critical questions: Is the study population similar to ...

Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold ...